Company intelligence / Profile preview

InnoGene Biotech

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

InnoGene Biotech (Younuojin) is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative gene therapies and oncolytic viruses. The company's core focus is on treating refractory cancers and malignant effusions through its proprietary recombinant oncolytic adenovirus technologies. Its lead candidate, YN601 (an oncolytic adenovirus expressing interferon-beta), has demonstrated promising clinical results in treating malignant pleural effusion and various solid tumors. InnoGene aims to address unmet medical needs in oncology by combining viral-mediated cell lysis with localized immune activation.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyGene therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on InnoGene Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoGene Biotech.

Explore the full profile